Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Study to Evaluate the Pharmacokinetic, Efficacy, Safety, and Immunogenicity Profiles of HLX05-N vs. ERBITUX® (US/EU-sourced) in Participants With Metastatic Colorectal Cancer

NCT07543471 is registered in ClinicalTrials.gov with Shanghai Henlius Biotech as lead sponsor.

NCT NCT07543471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07543471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Study to Evaluate the Pharmacokinetic, Efficacy, Safety, and Immunogenicity Profiles of HLX05-N vs. ERBITUX® (US/EU-sourced) in Participants With Metastatic Colorectal Cancer
Lead sponsor
Shanghai Henlius Biotech
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
April 30, 2028
Enrollment
387 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

mcrc